Exicure (XCUR) Competitors $10.04 -0.47 (-4.47%) Closing price 03:59 PM EasternExtended Trading$10.06 +0.03 (+0.25%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XCUR vs. ATYR, ATAI, ACB, AQST, CMPX, DBVT, CRVS, IMMP, AURA, and CGCShould you be buying Exicure stock or one of its competitors? The main competitors of Exicure include Atyr PHARMA (ATYR), Atai Life Sciences (ATAI), Aurora Cannabis (ACB), Aquestive Therapeutics (AQST), Compass Therapeutics (CMPX), DBV Technologies (DBVT), Corvus Pharmaceuticals (CRVS), Immutep (IMMP), Aura Biosciences (AURA), and Canopy Growth (CGC). These companies are all part of the "pharmaceutical products" industry. Exicure vs. Atyr PHARMA Atai Life Sciences Aurora Cannabis Aquestive Therapeutics Compass Therapeutics DBV Technologies Corvus Pharmaceuticals Immutep Aura Biosciences Canopy Growth Atyr PHARMA (NASDAQ:ATYR) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability, community ranking and analyst recommendations. Is ATYR or XCUR more profitable? Atyr PHARMA's return on equity of -79.44% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets Atyr PHARMAN/A -79.44% -59.16% Exicure N/A -190.90%-36.75% Does the media favor ATYR or XCUR? In the previous week, Atyr PHARMA had 8 more articles in the media than Exicure. MarketBeat recorded 8 mentions for Atyr PHARMA and 0 mentions for Exicure. Atyr PHARMA's average media sentiment score of 0.82 beat Exicure's score of 0.00 indicating that Atyr PHARMA is being referred to more favorably in the media. Company Overall Sentiment Atyr PHARMA Positive Exicure Neutral Which has stronger valuation and earnings, ATYR or XCUR? Exicure has higher revenue and earnings than Atyr PHARMA. Atyr PHARMA is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtyr PHARMA$235K1,420.28-$50.39M-$0.81-4.63Exicure$500K126.87-$16.91M-$4.81-2.09 Does the MarketBeat Community prefer ATYR or XCUR? Atyr PHARMA received 5 more outperform votes than Exicure when rated by MarketBeat users. Likewise, 100.00% of users gave Atyr PHARMA an outperform vote while only 47.37% of users gave Exicure an outperform vote. CompanyUnderperformOutperformAtyr PHARMAOutperform Votes14100.00% Underperform VotesNo VotesExicureOutperform Votes947.37% Underperform Votes1052.63% Do analysts prefer ATYR or XCUR? Atyr PHARMA presently has a consensus target price of $18.60, suggesting a potential upside of 396.00%. Given Atyr PHARMA's stronger consensus rating and higher probable upside, equities analysts clearly believe Atyr PHARMA is more favorable than Exicure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atyr PHARMA 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Exicure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, ATYR or XCUR? Atyr PHARMA has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Exicure has a beta of 3.86, suggesting that its stock price is 286% more volatile than the S&P 500. Do institutionals & insiders have more ownership in ATYR or XCUR? 61.7% of Atyr PHARMA shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 3.7% of Atyr PHARMA shares are held by insiders. Comparatively, 3.9% of Exicure shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryAtyr PHARMA beats Exicure on 13 of the 18 factors compared between the two stocks. Get Exicure News Delivered to You Automatically Sign up to receive the latest news and ratings for XCUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XCUR vs. The Competition Export to ExcelMetricExicurePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$63.43M$6.47B$5.33B$8.31BDividend YieldN/A2.64%5.20%4.10%P/E Ratio-4.858.4026.7219.60Price / Sales126.87258.84395.56117.96Price / CashN/A65.8538.3234.62Price / Book5.746.416.764.50Net Income-$16.91M$143.73M$3.23B$248.40M7 Day Performance-0.20%0.35%0.41%-1.00%1 Month Performance-10.83%2.05%9.12%10.72%1 Year Performance2,141.07%-0.65%18.73%9.00% Exicure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XCURExicure1.4592 of 5 stars$10.04-4.5%N/A+2,137.2%$63.43M$500,000.00-4.8550ATYRAtyr PHARMA2.671 of 5 stars$3.24-1.2%$18.60+474.1%N/A$288.37M$235,000.00-3.4553Positive NewsATAIAtai Life Sciences2.3039 of 5 stars$1.44+3.6%$10.50+629.2%+21.0%$287.71M$308,000.00-1.7880News CoverageAnalyst ForecastAnalyst RevisionACBAurora Cannabis0.752 of 5 stars$5.06+4.3%N/A-19.9%$284.44M$320.81M101.221,340Positive NewsGap DownAQSTAquestive Therapeutics1.2929 of 5 stars$2.85+2.2%$10.67+274.3%-27.3%$283.07M$57.56M-6.33160Gap DownCMPXCompass Therapeutics3.8842 of 5 stars$2.01+10.4%$13.13+553.0%+34.6%$277.95M$850,000.00-5.4320Positive NewsGap DownDBVTDBV Technologies2.8249 of 5 stars$10.13+3.1%$15.50+53.0%+41.9%$277.46M$15.73M-2.2580CRVSCorvus Pharmaceuticals2.1969 of 5 stars$4.05-8.6%$16.33+303.3%+62.1%$276.08MN/A-4.3530Analyst ForecastHigh Trading VolumeIMMPImmutep1.2517 of 5 stars$1.87+1.1%$8.50+354.5%-36.9%$270.17M$5.14M0.002,021Analyst UpgradeGap DownAURAAura Biosciences2.8314 of 5 stars$5.35+2.3%$22.75+325.2%-17.0%$268.70MN/A-3.0950Positive NewsAnalyst ForecastInsider TradeGap DownCGCCanopy Growth0.8877 of 5 stars$1.46+11.5%$2.00+37.0%-79.5%$268.44M$276.75M-0.383,150Trending NewsUpcoming Earnings Related Companies and Tools Related Companies Atyr PHARMA Alternatives Atai Life Sciences Alternatives Aurora Cannabis Alternatives Aquestive Therapeutics Alternatives Compass Therapeutics Alternatives DBV Technologies Alternatives Corvus Pharmaceuticals Alternatives Immutep Alternatives Aura Biosciences Alternatives Canopy Growth Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XCUR) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exicure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exicure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
